优化急性髓系白血病治疗：遗传学在新药物反应和耐药性评估中的作用
Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents.
作者信息
Halik Adriane, Arends Christopher Maximilian, Bullinger Lars, Damm Frederik, Frick Mareike
机构信息
Medical Department, Division of Hematology, Oncology, and Cancer Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, 13353 Berlin, Germany.
BIH Charité Junior Clinician Scientist Program, Berlin Institute of Health at Charité, BIH Biomedical Innovation Academy-Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany.
出版信息
Cancers (Basel). 2022 Mar 26;14(7):1689. doi: 10.3390/cancers14071689.
The number of treatment options for acute myeloid leukemia (AML) has greatly increased since 2017. This development is paralleled by the broad implantation of genetic profiling as an integral part of clinical studies, enabling us to characterize mutation-response, mutation-non-response, or mutation-relapse patterns. The aim of this review is to provide a concise overview of the current state of knowledge with respect to newly approved AML treatment options and the association of response, relapse and resistance with genetic alterations. Specifically, we will highlight current genetic data regarding FLT3 inhibitors, IDH inhibitors, hypomethylating agents (HMA), the BCL-2 inhibitor venetoclax (VEN), the anti-CD33 antibody conjugate gemtuzumab ozogamicin (GO) and the liposomal dual drug CPX-351.
自2017年以来，急性髓系白血病（AML）的治疗选择数量大幅增加。这一进展与基因谱分析作为临床研究不可或缺的一部分被广泛应用并行，使我们能够描绘突变反应、突变无反应或突变复发模式。本综述的目的是简要概述关于新批准的AML治疗选择以及反应、复发和耐药与基因改变之间关联的当前知识状态。具体而言，我们将重点介绍有关FLT3抑制剂、IDH抑制剂、低甲基化剂（HMA）、BCL-2抑制剂维奈克拉（VEN）、抗CD33抗体偶联物吉妥单抗（GO）和脂质体双药CPX-351的当前基因数据。
Zotero 插件